Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
报名条件(概要)
- 年龄:18 Years – 75 Years
- 性别:不限
- 健康志愿者:不接受
完整入排标准请以官方页面为准。
开展国家/地区
United States
药品与企业信息
其他名称:BIOPSY_TYPE、Bx
Undergo biopsy
其他名称:Biological Sample Collection、Biospecimen Collected、Specimen Collection
Undergo collection of blood samples
其他名称:CAT、CAT Scan、Computed Axial Tomography、Computerized Axial Tomography、Computerized axial tomography (procedure)、Computerized Tomography
Undergo CT scan
其他名称:(-)-Cyclophosphamide、2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate、Asta B 518、B-518、Carloxan、Ciclofosfamida
Given IV
其他名称:2-F-ara-AMP、9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-、Beneflur、Fludara、SH T 586
Given IV
其他名称:18FDG、FDG、Fludeoxyglucose (18F)、fludeoxyglucose F 18、Fludeoxyglucose F18、Fluorine-18 2-Fluoro-2-deoxy-D-Glucose
Undergo FDG-PET/CT scan
其他名称:IL13 [EQ]BBzeta/truncated CD19[t]+ Naive and Memory T Cells、IL13 [EQ]BBzeta/truncated CD19[t]+ TN/MEM Cells、IL13Ra2-specific-hinge-optimized-4-1BB-CAR/truncated CD19-expressing Autologous TN/MEM Lymphocytes
Given IV
其他名称:Magnetic Resonance、Magnetic Resonance Imaging (MRI)、Magnetic resonance imaging (procedure)、Magnetic Resonance Imaging Scan、Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance、MR
Undergo MRI
研发企业
试验官方登记的主要申办方;研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
合作机构
- Melanoma Research Alliance研究机构/其他
- California Institute for Regenerative Medicine (CIRM)研究机构/其他
- City of Hope National Medical Center研究机构/其他
- Jonsson Comprehensive Cancer Center研究机构/其他
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业;生产企业仅取自美国上市原研药说明书所列企业(不含仿制药),不作推测;仅在其他国家上市的药品暂无法显示。
研究简介(原文)
This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors that have spread to other places in the body (metastatic). The study agent is called IL13Ralpha2 CAR T cells. T cells are a special type of white blood cell (immune cells) that have the ability to kill tumor cells. The T cells are obtained from the patient's own blood, grown in a laboratory, and modified by adding the IL13Ralpha2 CAR gene. The IL13Ralpha2 CAR gene is inserted into T cells with a virus called a lentivirus. The lentivirus allows cells to make the IL13Ralpha2 CAR protein. This CAR has been designed to bind to a protein on the surface of tumor cells called IL13Ralpha2. This study is being done to determine the dose at which the gene-modified immune cells are safe, how long the cells stay in the body, and if the cells are able to attack the cancer.
适应症
主动联系研究团队
这项试验目前在中国大陆没有研究中心
这种情况下,直接发"入组咨询"往往会被回复"您所在地区没有中心"。更有效的做法是申请同情用药/扩展准入(由主治医生一同提出),或询问能否到最近的境外中心参加。下面已为您切换到对应的信件版本。
查看完整申请路径与成功率说明 →总联系人(申办方/研究总部)
- Lucie M Cutlerluciecut@stanford.eduluciecut@stanford.edu
研究中心联系方式
- City of HopeDuarte,California,United States
- UCLA / Jonsson Comprehensive Cancer CenterLos Angeles,California,United States
- Stanford Cancer InstituteStanford,California,United States
问自己是否符合条件、如何预筛
我的病情档案
档案只保存在您自己的浏览器里,不会上传,任何人(包括本站)都看不到。
英文版(发给研究团队)
Dear Study Team, I am a patient in China and I am interested in participating in your clinical trial: Study Title: Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors ClinicalTrials.gov Identifier: NCT04119024 Sponsor: Anusha Kalbasi Investigational product: Biopsy, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine Phosphate About me: - Age: (please fill in) - Sex: (please fill in) - Confirmed diagnosis and stage: (please fill in) - Biomarkers / genetic testing: not available - Prior and current treatments: (please fill in) - Performance status (ECOG): not assessed - Current location: China - Travel ability: (please fill in) Could you please let me know: 1. Whether I might be eligible for this study; 2. Which site would be closest and most practical for me, and whether remote pre-screening is possible; 3. What documents (medical records, pathology or imaging reports, recent labs) I should prepare for pre-screening. I can provide English translations of my medical records. Thank you very much for your time and help. Kind regards, (your name) (your email / phone with country code)
中文对照(供您核对)
尊敬的研究团队: 我是一位来自中国的患者,希望咨询参加以下临床试验的可能: 研究名称:Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors 试验编号:NCT04119024 申办方:Anusha Kalbasi 研究药物:Biopsy、Biospecimen Collection、Computed Tomography、Cyclophosphamide、Fludarabine Phosphate 我的基本情况: - 年龄:(请填写) - 性别:(请填写) - 确诊疾病与分期:(请填写) - 基因/标志物检测:暂无 - 既往及当前治疗:(请填写) - 体能状态(ECOG):未评估 - 目前所在城市:中国 - 可前往范围:(请填写) 想请教三个问题: 1. 我是否可能符合本研究的入组标准? 2. 哪个中心对我最方便可行?能否远程预筛? 3. 预筛需要准备哪些资料(病历、病理、影像、近期化验)? 我可以提供英文翻译版病历。感谢您的时间与帮助。 顺祝安康 (您的姓名) (您的邮箱/带国际区号的电话)
提示:请与主治医生一起发信——由医生署名的申请,回复率远高于患者单独发信。首封邮件不要附身份证号等敏感信息。研究团队通常在 3–10 个工作日内回复,两周无回音可礼貌追问一次。
下一步怎么做?
- 把本页信息带给您的主治医生,评估是否适合参加。
- 点击下方按钮打开官方注册页,查看研究中心联系方式。
- 直接联系研究团队咨询报名事宜(通常有中文同声翻译服务可协助沟通)。